Abstract:FTY720 is a synthetic analogue of sphingosine 1‐phosphate. It is currently used to treat multiple sclerosis and has recently been approved for use in adolescents. The aim of this study was to investigate how FTY720 alters the lipid composition of the brain of adolescent mice. Three weeks of chronic FTY720 treatment caused an up‐regulation of 99 lipid species in the mouse hippocampus, including several oxidised phosphatidylcholines, whereas only 3 lipid species of the phosphatidic acid class were down‐regulated. Our study presents novel insight into FTY720's molecular mechanism of action in the central nervous system. FST, forced swim test; LC‐MS/MS, liquid chromatography–tandem mass spectrometry; MUFAs, monounsaturated fatty acids; MWM, Morris water maze; OFT, open field test; PCOH, hydroxy‐phosphatidylcholine; PND, postnatal day; PUFAs, polyunsaturated fatty acids; S1P, sphingosine 1‐phosphate; S1PR, sphingosine 1‐phosphate receptor. The small‐molecule drug, FTY720 (fingolimod), is a synthetic sphingosine 1‐phosphate (S1P) analogue currently used to treat relapsing–remitting multiple sclerosis in both adults and children. FTY720 can cross the blood–brain barrier (BBB) and, over time, accumulate in lipid‐rich areas of the central nervous system (CNS) by incorporating into phospholipid membranes. FTY720 has been shown to enhance cell membrane fluidity, which can modulate the functions of glial cells and neuronal populations involved in regulating behaviour. Moreover, direct modulation of S1P receptor‐mediated lipid signalling by FTY720 can impact homeostatic CNS physiology, including neurotransmitter release probability, the biophysical properties of synaptic membranes, ion channel and transmembrane receptor kinetics, and synaptic plasticity mechanisms. The aim of this study was to investigate how chronic FTY720 treatment alters the lipid composition of CNS tissue in adolescent mice at a key stage of brain maturation. We focused on the hippocampus, a brain region known to be important for learning, memory, and the processing of sensory and emotional stimuli. Using mass spectrometry‐based lipidomics, we discovered that FTY720 increases the fatty acid chain length of hydroxy‐phosphatidylcholine (PCOH) lipids in the mouse hippocampus. It also decreases PCOH monounsaturated fatty acids (MUFAs) and increases PCOH polyunsaturated fatty acids (PUFAs). A total of 99 lipid species were up‐regulated in the mouse hippocampus following 3 weeks of oral FTY720 exposure, whereas only 3 lipid species were down‐regulated. FTY720 also modulated anxiety‐like behaviours in young mice but did not affect spatial learning or memory formation. Our study presents a comprehensive overview of the lipid classes and lipid species that are altered in the hippocampus following chronic FTY720 exposure and provides novel insight into cellular and molecular mechanisms that may underlie the therapeutic or adverse effects of FTY720 in the central nervous system.

Fingolimod phosphoramidate prodrugs: Synthesis, photophysical characterisation and lipid bilayer interaction of fluorescent tagged Prodrug.

The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives

ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P1 Agonist and Functional Antagonist Potency In Vitro and In Vivo

The emerging role of FTY720 as a sphingosine 1‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms

Novel triazine-tyrosine hybrids containing thiyazol or pyridine fragment as anti-multiple sclerosis agents: Design, synthesis, biological evaluation, and molecular docking study

The sphingosine 1‐phosphate analogue, FTY720, modulates the lipidomic signature of the mouse hippocampus

Lipidation-dimerization Platform Unlocks Treatment Potential of Fibroblast Growth Factor 21 for Non-Alcoholic Steatohepatitis

Discovery of indoximod prodrugs and characterization of clinical candidate NLG802

Pharmacological Effects of FTY720 and its Derivatives

Fibroblast growth factor receptor modulators employing diamines with reduced phospholipidosis-inducing potential

Pharmacokinetic and Biodistribution Study Following Systemic Administration of Fospeg® – a Pegylated Liposomal Mthpc Formulation in a Murine Model

Fingolimod Targets Cerebral Endothelial Activation To Block Leukocyte Recruitment In The Central Nervous System

Design, synthesis and biological evaluation of aryloxy thiophosphoramidate triesters of anticancer nucleoside analogues

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects

Hybrid derivatives containing dimethyl fumarate and benzothiazole scaffolds for the potential treatment of multiple sclerosis; in silico & in vivo study

Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs

FTY720 for Cancer Therapy (Review)

Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells

Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy

Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database

Suzuki Coupling Based Synthesis and in Vitro Cytotoxic Evaluation of Fingolimod and Analogues